Sigyn Therapeutics (SIGY) Work In Process (2016 - 2018)

Sigyn Therapeutics (SIGY) posted Work In Process of $121411.0 for Q3 2018, up 1.85% sequentially from $119211.0 in Q2 2018.

Sigyn Therapeutics (SIGY) Work In Process (2016 - 2018) Analysis & Trends

Sigyn Therapeutics has reported Work In Process for 3 years, with the latest figure at $121411.0 in Q3 2018.

Quarterly Work In Process changed N/A year-over-year to $121411.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $121411.0 (changed N/A YoY) and the FY2017 annual result came in at $117012.0, changed N/A from the prior year.
Work In Process climbed to $121411.0 in Q3 2018 per SIGY's latest filing, from $119211.0 in the prior quarter.
Over five years, Work In Process peaked at $121411.0 in Q3 2018 and troughed at $111361.0 in Q4 2016.
A 3-year average of $116803.0 and a median of $118111.5 in 2017 frame the typical range for Work In Process.
The sharpest annual moves came in 2017 and 2018: Work In Process rose 5.07% in 2017, then grew 5.86% in 2018.
Over 3 years, Work In Process stood at $111361.0 in 2016, then advanced by 5.07% to $117012.0 in 2017, then rose by 3.76% to $121411.0 in 2018.
According to Business Quant data, Work In Process over the past three periods registered $121411.0, $119211.0, and $119212.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Sigyn Therapeutics	48,161.31	-37,409.69	-

Download Data